‹ Compliance and regulatory specialist agents

Scoop

Automating regulatory submissions for life sciences

scooplabs.ai

1.2Score#965 of 999 agents#25 of 25 in Compliance and regulatory specialist

Visit site Compare

Why it ranks #965

Scoop, an AI compliance and regulatory specialist from YC F25, ranks #965 of 999 AI agents and #25 of 25 in Compliance and regulatory specialist, with a score of 1.2 of 10. Data as of 3 Oct 2026.

The score adds four parts, each 0 to 10, by weight. Every point comes from public evidence. How scoring works ·

Proof 0 × 30% 0.0
Scale 1 × 30% 0.3
Momentum 0 × 25% 0.0
Autonomy 6 × 15% 0.9
= 1.2

Proof
Do customers use it? 30% of the score
0
No public claims of customers or revenue yet.
Not found: revenue or growth (+4), named customers (+3), a customer result (+2), a customer count (+2), work done at scale (+2)
Scale
Is there a real company behind it? 30% of the score
1
2 people.
- +1
  2 people on its YC page2 people
Not found: funding round in its news (+3)
Momentum
Is it shipping and growing now? 25% of the score
0
Nothing new in the last 6 months.
Not found: launch YC post in the last 6 months (+3), open roles on YC (+2), new traction claim in the last 6 months (+2), funding news in the last year (+2), a batch in the last year (it is YC Fall 2025) (+1)
Autonomy
How much of the job does it do on its own? 15% of the score
6
Supervised agent: takes actions in other systems; a person approves key steps.
- +6
  Level 2 of 4: Supervised agentTakes actions in other systems; a person approves key steps.
What the model read
- Acts in other systems: 48% likely
- Finishes whole tasks: 27% likely
- Calls itself an agent: 97% likely
- Level 1 from the model's reading of its pages; the evidence review found, with quotes, that its AI acts in the work, so the level is 2
Level 2: Takes actions in other systems; a person approves key steps.

About Scoop

We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.